Recent Updates
Recently added Catalysts

LB2102

Phase 1

Small Cell Lung Cancer Extensive Stage | Monoclonal antibody | Oncology |Legend Biotech Corporation|Last Updated: Mar 24, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment41
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05680922DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung CancerPHASE1 ACTIVE NOT_RECRUITING 41 — — Jul 26, 2023Dec 1, 2027Mar 24, 20264 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE)
28 days

Multiple doses will be tested to establish a recommended dose

To further characterize the safety and tolerability of LB2102 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D)
90 days

Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study

Secondary Endpoints
To evaluate the preliminary efficacy of LB2102
Through study completion, a minimum of 2 years
To characterize the pharmacokinetics of LB2102 in blood
Through study completion, a minimum of 2 years
To evaluate the immunogenicity of LB2102
Through study completion, a minimum of 2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Experimental LB2102EXPERIMENTALDLL3-Directed Chimeric Antigen Receptor T-cells (CAR T)
Interventions
NameTypeDescription
LB2102BIOLOGICALDLL3 directed autologous Chimeric Antigen Receptor T-cells
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Be at least 18 years of age and willing and able to provide a written informed consent * Have histologically/cytologically confirmed unresectable small cell lung carcinoma (SCLC), large cell neuroendocrine lung carcinoma (LCNEC), combined SCLC, or combined LCNEC as per WHO 202...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT05680922Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 24, 2026NCT05680922studyFirstPostDate: changed